louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01403831: Trial to Examine Text-message Based mHealth in Emergency Department Patients With Diabetes
Official title: Trial to Examine Text-message Based mHealth in Emergency Department Patients With Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes
Lead sponsor: University of Southern California
Sponsor class: OTHER
First posted: 2011-07-27
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The investigators propose an innovative, ED-based mHealth intervention: TExT-MED (Trial to Examine Text-Based mHealth for Emergency department patients with Diabetes). TExT-MED is a technologically simple solution using unidirectional daily text messages to consisting of educational materials, trivia questions and challenges promoting healthy lifestyle choices and reminders to check blood sugar, take medications and go to clinic appointments. The investigators believe TExT-MED will improve health outcomes including blood glucose control and encourage weight loss, healthy eating and exercise. TExT-MED is low cost, easy to use and can be quickly adapted to other practice environments.


Eligibility criteria: Inclusion Criteria:

1) ≥18 years old 2) have Type 2 diabetes 3) have a text message capable mobile phone 4) know how to receive text messages 5) speak and read English or Spanish and 6) have a HbA1C ≥8%.

Exclusion Criteria:

1) overt psychosis 2) unable to provide informed consent and 3) pregnancy.

Primary outcomes:
measure: Hemoglobin A1C at 6 months
timeFrame: 6 months
Secondary outcomes:
measure: DIet/ Weight Loss
timeFrame: 6 months
measure: Diabetes self-efficacy/empowerment
timeFrame: 6 months
measure: Diabetes knowledge
timeFrame: 6 months
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: University of Southern California
state: California
Study officials:
References:
citation: Arora S, Peters AL, Agy C, Menchine M. A mobile health intervention for inner city patients with poorly controlled diabetes: proof-of-concept of the TExT-MED program. Diabetes Technol Ther. 2012 Jun;14(6):492-6. doi: 10.1089/dia.2011.0252. Epub 2012 Apr 23.
Clinical trial NCT04477031: Verification of the Safety of Normal Food Before a Cerebral Arteriography
Official title: Verification of the Safety of Normal Food Before a Cerebral Arteriography
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cerebral Angiography
Keywords: Fasting
non fasting
cerebral angiography
nausea
vomiting
Lead sponsor: Nantes University Hospital
Sponsor class: OTHER
First posted: 2020-07-20
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients benefiting from a cerebral arteriography, within the UMCA of the North Laënnec Hospital.

Brief summary: Fasting is currently required before elective cerebral angiography, despite numerous arguments against fasting (kidney toxicity, vasovagal reaction, discomfort) and seams unusefull regarding it's main goal : reducing nausea and vomiting. The investigators propose to assess frequency of nausea and vomiting among patients having taken their breakfast at home before day care angiography.

The investigators hypothesise that less than 1% of non fasting patients will suffer of vomitint.

Detailed description: Fasting is currently required before elective cerebral angiography, despite numerous arguments against fasting (kidney toxicity, vasovagal reaction, discomfort) and seams unusefull regarding it's main goal : reducing nausea and vomiting. The investigators propose to assess frequency of nausea and vomiting among patients having taken their breakfast at home before day care angiography.

The investigators hypothesise that less than 1% of non fasting patients will suffer of vomitint.

Eligibility criteria: Inclusion Criteria:

* Adult,
* non fasting,
* day care hosptilalisation

Exclusion Criteria:

* Childs,
* pregnancy,
* parenteral nutrition,
* nausea,
* vomiting before arteriography,
* arteriography under general anesthesia

Primary outcomes:
measure: frequency of vomiting during arteriographic procedure
timeFrame: fifteen minutes
Secondary outcomes:
measure: nausea
timeFrame: fifteen minutes
Other outcomes:
Locations:
city: Nantes
country: France
facility: CHU de Nantes
Study officials:
affiliation: Nantes University Hospital
name: Benjamin Daumas-Duport, ph
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02086331: Evaluation of Musculoskeletal Microcirculation With Ultrasound
Official title: Evaluation of Musculoskeletal Microcirculation With Ultrasound
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Standardised Claudication Treadmill Test
Keywords: treadmill test
Lead sponsor: Imperial College London
Sponsor class: OTHER
First posted: 2014-03-13
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This study aims to validate the use of Dynamic Contrast-Enhanced Ultrasound in measuring the blood supply to the muscles of the leg, and how this changes with exercise and vascular pathology.

Detailed description: We propose a model for the use of Dynamic Contrast-Enhanced Ultrasound (DCEU) to directly evaluate the microcirculation of the musculoskeletal system. We believe that this will be a valuable research tool into diseases of the microcirculation, and in the future may also offer a clinical benefit by quantifying and monitoring disease over time and after intervention. It may also allow targeting of therapies towards those patients most at risk of ulcers and peripheral neuropathy, and those that would get the maximum benefit from these therapies.

Eligibility criteria: Group 1 - Healthy subjects Inclusion

* 18+ years old

Exclusion

* Personal history of diabetes or peripheral arterial disease, current pregnancy, previous surgery to the lower limb, heart attack within 4 weeks, or unstable angina

Group 2 - Peripheral arterial disease subjects Inclusion

* 18+ years old, radiological evidence of peripheral arterial disease (arterial doppler or angiogram), ankle-brachial pressure index (ABPI) 0.5-0.8

Exclusion

* Personal history of diabetes, current pregnancy, previous amputation, heart attack within 4 weeks, or unstable angina

Group 3 - Diabetic subjects Inclusion

* 18+ years old, with a clinical diagnoses of diabetes (1, 2)

Exclusion

- ABPI\<0.9, previous amputation, current pregnancy or breastfeeding, heart attack within 4 weeks, or unstable angina.

Primary outcomes:
measure: Threshold of High to Low Frequency Ratio (Threshold HLFR)
timeFrame: Baseline, 20 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Charing Cross Hospital
Study officials:
affiliation: Imperial College London
name: Prof AH Davies
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03175731: PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)
Official title: A Randomized Controlled Study on the Effects of PPIs on Gastroesophageal Variceal Bleeding in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Liver Cirrhosis
Hypertension, Portal
Keywords: Gastroesophageal varices
Hemorrhage
Lead sponsor: Qilu Hospital of Shandong University
Sponsor class: OTHER
First posted: 2017-06-05
Enrollment: 106
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is aimed at investigating the effect of PPIs on gastroesophageal varices in liver cirrhosis. Half of participants will receive PPI, while the other half will receive a placebo.

Detailed description: PPIs can inhibit parietal cell H+/K+-ATPase and reduce secretion of gastric acid. PPIs can promote platelet aggregation and stabilize the formation of fibrin thrombosis by maintaining the high pH environment in the stomach and inactivating pepsin. The effect of PPIs on ulcerative upper gastrointestinal bleeding was confirmed but it is not clear whether PPIs is applicable in esophagogastric variceal bleeding whose etiology and bleeding position are different from ulcerative upper gastrointestinal bleeding. There is lack of consensus and sufficient evidences to support to use PPIs in esophagogastric variceal bleeding in cirrhotic patients universally. Nevertheless, the use of PPIs in liver cirrhotic patients with gastroesophageal varices is common.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of cirrhosis
* GEVs was diagnosed by endoscopy

Exclusion Criteria:

* Acute gastrointestinal bleeding need emergency surgery
* Acid-related disease, such as peptic ulcer disease or gastroesophageal reflux diseases (GERD)
* Hepatocellular carcinoma (HCC) or other malignant tumor
* History of esophagus, stomach or liver surgery
* Child-Pugh C and can't be improved to Child-Pugh A or B
* Preparing to be pregnant, pregnant or breast feeding
* Allergic to PPIs(proton pump inhibitors) or intolerable
* Cannot provide informed consent

Primary outcomes:
measure: Variceal Bleeding Events
timeFrame: 8 weeks
Secondary outcomes:
measure: Mortality
timeFrame: 8 weeks
measure: Adverse Eventsafter Endoscopic Therapy
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Jinan
country: China
facility: Department of Gastroenterology,Qilu Hospital,Shandong University
state: Shandong
Study officials:
affiliation: Qilu Hospital, Shandong University
name: Yanjing /A Gao, PhD.MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03151031: Effect on Dynamic Postural Stability After Application of Cryotherapy to the Knee Joint
Official title: Effect on Dynamic Postural Stability After Application of Cryotherapy to the Knee Joint: A Pilot Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cryotherapy Effect
Balance; Disorder, Fluid
Keywords: balance
college students
star excursion balance test
Lead sponsor: Maharishi Markendeswar University (Deemed to be University)
Sponsor class: OTHER
First posted: 2017-05-12
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study will determine the effect of cryotherapy applied to the knee joint on static and dynamic standing balance. It is hypothesized that there will be no change in dynamic postural stability after cryotherapy application.Twenty four individuals (age 18 to 30) participated in the study. They will be randomly divided into two groups, experimental and control group. Each participant, in the experimental group will be asked to perform star excursion balance test (SEBT) under two conditions, before and after the application of cryotherapy. The participants will receive ice pack wrapping of the knee for 10 minutes. The control group performed SEBT at room temperature in an interval of 10 minutes. The two group will be analysed and compared

Detailed description: The cooling procedure for the knee joint was initiated by using a cryopack or cold-pack. On completion of the initial SEBT, the participant lied supine and the investigator applied the cryotherapy for 10 minutes. After the 10 minute period of cryotherapy, the cryopack was removed, and the participants performed SEBT for the second time.

Eligibility criteria: Inclusion Criteria:

* Normal adult person.
* Aged between 18 to 30 year
* Both male and female were included in the study

Exclusion Criteria:

* Adult having any visual impairment
* Adult having any vestibular impairment
* Adult suffering from any neurological disorders
* Adult suffering from other medical conditions, like- Vascular diseases
* Adult having any disorders or conditions like- Genu valgum, Genu varum, history of knee joint or lower limb injury, or lower limb fracture

Primary outcomes:
measure: Change from Baseline Star Excursion Balance test at 10 minutes
timeFrame: Upto 10 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Ambala
country: India
facility: Asir John Samuel
state: Haryana
Study officials:
affiliation: Maharishi Markandeshwar Institute of physiotherapy and Rehabilitation
name: Asir J Samuel, MPT
role: STUDY_DIRECTOR
References:
Clinical trial NCT06671431: Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma
Official title: Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma: a Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Distal Cholangiocarcinoma
Adjuvant Chemotherapy
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2024-11-04
Enrollment: 578
Sex: ALL
Minimum age (years): 19
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with distal cholangiocarcinoma who underwent curative surgery

Brief summary: Recent studies addressing the role of adjuvant chemotherapy in cholangiocarcinoma (CCA) have been published; however, there are challenges in generalizing the findings due to different prognostic characteristics depending on tumor location and resectability. Therefore, the aim of this study was to investigate the role of AC in distal cholangiocarcinoma, a common tumor subtype of CCA.


Eligibility criteria: Inclusion Criteria:

* Patients with distal cholangiocarcinoma who underwent surgery

Exclusion Criteria:

* Who underwent neoadjuvant treatment
* Who underwent R2 resection
* Non-adenocarcinoma patients in final pathology report
* Insufficient data
* Death within 90days of surgery

Primary outcomes:
measure: Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma
timeFrame: From January 2000 to December 2021
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06074731: Diagnostic Possibilities in Ophthalmological Diseases Using Swept Source Optical Coherence Tomography
Official title: Diagnostic Possibilities in Ophthalmological Diseases Using Swept Source Optical Coherence Tomography
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Retinal Disease
Diabetic Retinopathy
Macular Degeneration
Lead sponsor: Johannes Kepler University of Linz
Sponsor class: OTHER
First posted: 2023-10-10
Enrollment: 500
Sex: ALL
Minimum age (years): 5
Maximum age (years): 110
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The participants will be selected by the Department of Ophthalmology at Kepler University Clinic Linz. All patients of the department scheduled for an outgoing appointment with regular examination in the time period of the study can be included in the study. Patients are being examined in the outgoing clinics with standard examinations. Additionally an image using the Zeiss Plex Elite 9000 Swept Source OCT is being performed. Patients of interest for this pilot study are patients with retinal, choroidal, vascular or glaucomatous changes.

Brief summary: In this pilot study we want to investigate morphological features acquired by the novel image modality and gain information regarding disease pathomechanism, development and future possible influence on disease management for patients affected by those diseases.


Eligibility criteria: Inclusion Criteria:

* Age between 5 and 110 years
* Ability to follow instructions during imaging procedure
* Written Informed consent

Exclusion Criteria:

* Dementia
* Inability to follow instructions during imaging procedure
* Patients who do not give informed consent

Primary outcomes:
measure: Morphological changes using Swept Source Optical Coherence Tomography
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Linz
country: Austria
facility: Department for Ophthalmology and Optometry, Kepler University Hospital GmbH, Johannes Kepler University Linz, Altenberger Strasse 69, 4040 Linz, Austria
state: Oberösterreich
Study officials:
affiliation: Department for Ophthalmology, Kepler University Hospital GmbH, Johannes Kepler University Linz, Altenberger Strasse 69, 4040 Linz, Austria
name: Matthias Bolz, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00405431: Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?
Official title: Influence of Post-Operative Cyclosporine 0.05% (Restasis) on the Success of Glaucoma Filtering Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glaucoma
Keywords: glaucoma filtering surgery
restasis
conjunctival inflammation
Lead sponsor: Wills Eye
Sponsor class: OTHER
Collaborators: name: Allergan
First posted: 2006-11-30
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether reducing inflammation of the surface of the eye with topical Restasis after glaucoma surgery will improve surgical outcomes and increase patient comfort.

Detailed description: Continued use of glaucoma drops can alter the outer surface of the eye and result in swelling and irritation, changing the structure of the eye. This structural change has been found to be a significant risk factor for the failure of glaucoma surgery. A comparison of how well patients do after glaucoma surgery depending on whether they use Restasis (the only prescription medication approved by the FDA for treating dry eye) or artificial tears (which can be purchased without a prescription) for 6 months following their surgery.

Eligibility criteria: Inclusion Criteria:

* Patients with uncontrolled glaucoma scheduled for filtering surgery

Exclusion Criteria:

* Under 18 years of age
* Unable to understand informed consent

Primary outcomes:
measure: intraocular pressure
timeFrame: 6 months
Secondary outcomes:
measure: ocular inflammation
timeFrame: 6 months
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Wills Eye Glaucoma Service
state: Pennsylvania
Study officials:
affiliation: Wills Eye Glaucoma Research Center
name: Marlene R. Moster, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Fakhraie G, Lopes JF, Spaeth GL, Almodin J, Ichhpujani P, Moster MR. Effects of postoperative cyclosporine ophthalmic emulsion 0.05% (Restasis) following glaucoma surgery. Clin Exp Ophthalmol. 2009 Dec;37(9):842-8. doi: 10.1111/j.1442-9071.2009.02134.x.
Clinical trial NCT01528631: The Effects of D-Fagomine on Glycaemic Response to Sucrose in Men
Official title: Randomized Controlled Double-blind Nutritional Intervention Trial to Evaluate the Effects of D-fagomine on Glycaemic Response to Sucrose in Men
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glycaemic Response
Insulinemic Response
Lead sponsor: Bioglane
Sponsor class: INDUSTRY
Collaborators: name: University Rovira i Virgili
name: Technological Centre of Nutrition and Health
name: National Research Council, Spain
First posted: 2012-02-08
Enrollment: 12
Sex: MALE
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of this study is to evaluate the effect of D-fagomine on glycaemic response to sucrose in men.

Detailed description: To determine and compare glycaemic response to sucrose of D-Fagomine and control in the timeframe of 180 minutes.

Eligibility criteria: Inclusion Criteria:

1. Males between the ages of 20 and 70 willing and able to provide written informed consent.

Exclusion Criteria:

1. LDL cholesterol levels higher than 189 mg/dl
2. Triglycerides higher than 350 mg/dl (the threshold level to determine c-LDL using the Friedewald formula)
3. Physical examinations and routine biochemical analysis shall be conducted to rule out pathologies.
4. Consumption of supplements or acetylsalicylic acid
5. Chronic alcoholism
6. Body mass index (BMI) greater than 30 kg/m2
7. Previous antihypertensive treatment at the start of the trial that has not finished at least 2 months before beginning the study
8. Diabetes mellitus (if the fasting blood glucose is higher than 126 mg/dl, the test should be repeated and confirmed)
9. Kidney disease (serum creatine levels above 1,4 mg/dl for women and above 1,5 mg/dl for men)
10. Acute infectious diseases, malignant tumors, severe liver failure, respiratory failure associated with chronic or endocrine diseases
11. Other conditions such as special dietary needs
12. To be participating or having participated in a clinical trial within the last 3 months
13. Inability to continue the study
14. History of gastrointestinal disease which may alter the absorption of nutrients
15. Depressive disorder or thoughts of self-injury

Primary outcomes:
measure: Glycaemic response to sucrose
timeFrame: 0-180 minutes
Secondary outcomes:
measure: Insulin in venous plasma
timeFrame: 0-180 minutes
Other outcomes:
Locations:
city: Reus
country: Spain
facility: Hospital Universitari Sant Joan, Universitat Rovira i Virgili
state: Tarragona
Study officials:
affiliation: University Rovira i Virgili
name: Rosa Solà, PhD MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gomez L, Molinar-Toribio E, Calvo-Torras MA, Adelantado C, Juan ME, Planas JM, Canas X, Lozano C, Pumarola S, Clapes P, Torres JL. D-Fagomine lowers postprandial blood glucose and modulates bacterial adhesion. Br J Nutr. 2012 Jun;107(12):1739-46. doi: 10.1017/S0007114511005009. Epub 2011 Oct 3.